



Fort Dodge Animal Health

Division of Wyeth
Huizerstraatweg 117
1411 GM NAARDEN
The Netherlands

15 June 2009

West Nile Virus Vaccine Now Available in Europe says Fort Dodge

Fort Dodge Animal Health has announced that its Duvaxyn® WNV vaccine against West Nile Virus (WNV) is now available in Europe, following its licensing through the European Medicines Agency (EMA). Duvaxyn® WNV is the first vaccine available in Europe to protect horses against this emerging disease threat. 288 horses and two people in Italy were found to be infected with WNV during the outbreak that hit northern Italy in late 2008 where it is now considered endemic. The disease is endemic in all areas of North America where it has claimed the lives of both horses and humans.

West Nile Virus is caused by a highly contagious flavivirus, which is transmitted by mosquitoes, primarily of the *Culex* species. The natural hosts of West Nile virus are birds, with migratory birds from Africa carrying the disease. Mosquitoes become infected after taking a blood meal from infected birds and then may transmit the disease to horses and even humans. While horses are 'dead end hosts,' the consequences can be severe as the virus causes encephalitis or meningitis. Mortality rates among horses which develop neurological signs are high and there is no palliative cure for the disease. Treatment is limited to symptomatic relief which can be long and expensive.

"WNV is an increasing threat to the equestrian sector in Europe and is a particular challenge for owners who transport their horses around the world," says Helen Barnes, Equine Business Manager for Fort Dodge EMA. "The fact that a vaccine is now available will undoubtedly offer peace of mind to the equestrian community. They can be reassured that



horses in Europe can now be vaccinated against WNV with a vaccine that has already been shown to be highly effective in protecting horses in America.

“With any vaccine, a record that a horse has been vaccinated with Duvaxyn® WNV should be recorded in its horse passport. By presenting this vaccine in pre-filled syringes with Infovax-ID® labels, we’ve aimed to make both the administration and record keeping of Duvaxyn® WNV as convenient as possible.

“To build understanding of this potentially fatal disease threat, we are continuing to work with governments and authorities at a national and European level, as well as working in partnership with the European veterinary community to ensure that owners are fully informed about the risk WNV poses and of the benefits of vaccination.”

Further information on WNV and Duvaxyn® WNV is available at www.westnile.eu.

Note to editors:

Fort Dodge Animal Health is a leading manufacturer and marketer of products for equine, livestock and small animal markets. Key products include Equest® horse wormer brands; Duvaxyn® equine vaccines; Cydectin® cattle and sheep wormer; Guardian™SR heartworm injection and a range of poultry and pig vaccines.

Fort Dodge Animal Health’s WNV vaccine is known in the U.S. as West Nile-Innovator™.

The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the



Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2007, which was filed with the Securities and Exchange Commission on February 29, 2008. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

For further information:

Fort Dodge Animal Health
(address of respective affiliate)